TransMedics Group, Inc. (NASDAQ:TMDX) Receives $171.44 Average Price Target from Analysts

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have received a consensus recommendation of “Moderate Buy” from the nine ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $171.44.

A number of research firms recently issued reports on TMDX. Cantor Fitzgerald assumed coverage on TransMedics Group in a research note on Thursday, June 6th. They issued an “overweight” rating and a $161.00 target price on the stock. Oppenheimer upped their price objective on TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a research report on Thursday, August 1st. Stephens lifted their price objective on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. TD Cowen upped their target price on shares of TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a report on Friday, June 7th. Finally, Piper Sandler lifted their price target on shares of TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st.

Insider Activity

In other news, insider Tamer I. Khayal sold 2,958 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $156.77, for a total transaction of $463,725.66. Following the transaction, the insider now directly owns 20,843 shares in the company, valued at approximately $3,267,557.11. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $156.77, for a total value of $463,725.66. Following the sale, the insider now owns 20,843 shares of the company’s stock, valued at $3,267,557.11. The disclosure for this sale can be found here. Insiders sold a total of 61,247 shares of company stock valued at $9,650,880 in the last 90 days. 7.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sanctuary Advisors LLC purchased a new position in shares of TransMedics Group in the 2nd quarter worth about $372,000. Teachers Retirement System of The State of Kentucky acquired a new stake in TransMedics Group during the 2nd quarter worth approximately $420,000. NewEdge Advisors LLC raised its holdings in TransMedics Group by 26.0% in the second quarter. NewEdge Advisors LLC now owns 10,372 shares of the company’s stock valued at $1,562,000 after buying an additional 2,140 shares during the period. Creative Planning raised its holdings in TransMedics Group by 78.3% in the second quarter. Creative Planning now owns 9,173 shares of the company’s stock valued at $1,382,000 after buying an additional 4,027 shares during the period. Finally, Algert Global LLC acquired a new position in TransMedics Group during the second quarter valued at approximately $2,685,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Trading Down 0.6 %

Shares of TMDX stock opened at $165.00 on Friday. The stock has a market cap of $5.43 billion, a P/E ratio of -485.29 and a beta of 1.99. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. TransMedics Group has a fifty-two week low of $36.42 and a fifty-two week high of $177.37. The business has a fifty day simple moving average of $155.65 and a 200-day simple moving average of $129.31.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The company had revenue of $114.30 million during the quarter, compared to analysts’ expectations of $98.84 million. During the same quarter in the previous year, the business posted ($0.03) earnings per share. The firm’s quarterly revenue was up 117.7% compared to the same quarter last year. On average, analysts forecast that TransMedics Group will post 1.23 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.